Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Eisai Inc.
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03250676CT.gov Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| h3b-6545 (this asset) | Eisai Inc. | P1/2 | CCC · 50 |
| Cyclophosphamide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P3 | BB |
| Adriamycin | Virginia Commonwealth University | P3 | BB |
| Trastuzumab | Academic and Community Cancer Research United | P3 | BB |
| Letrozole | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P4 | BB |
| Carboplatin | Genmab | P3 | BB |
| Pembrolizumab | Genmab | P2 | BB |
| Eribulin Monomethanesulfonate | Montefiore Medical Center | P3 | BB |
| Pertuzumab | Academic and Community Cancer Research United | P3 | BB |
+42 more in the Breast Adenocarcinoma cohort
Other indications for h3b-6545
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Neoplasm | — | P1/2 | CCC · 53 |
| HER2 Positive Breast Carcinoma | — | P1 | CC · 43 |
| Breast Cancer | — | P1/2 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. h3b-6545 in Breast Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/h3b-6545-breast-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →